NBIO
Nascent Biotech Inc.Company Information
- Company Name
- Nascent Biotech Inc.
- CIK
- CIK0001622057
- Category
- <br>Emerging growth company
- Ticker: Exchange
- NBIO: OTC
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-06-07
- Last sale
- 2022-07-21
- Shares purchased (TTM)
- 150,000
- Shares sold (TTM)
- 5,000
Institutional Sentiment
- As of
- 2024-03-31
- Institutional shares owned
- 105,000
- Shares outstanding
- 170,594,165
- Ownership
- 0.06%
Earnings Market Reaction
- Filing date
- 2024-08-14
- Price on filing date
- —
- 1-month reaction
- 8.60%
- 3-month reaction
- 86.05%
Balance Sheet
Values in millions ($)| Line item | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | - | - | - | - | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | 0 | 1 | 0 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | 0 | ||||||
| Assets | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Convertible Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Derivative Liabilities | - | - | - | - | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Due To Related Parties Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Derivative Liabilities Current | - | 0 | 0 | 0 | - | 1 | - | - | - | - | - | - | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Commitments And Contingencies | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | -1 | -0 | 0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -1 | ||||||
| Additional Paid In Capital | 24 | 24 | 24 | 23 | 21 | 20 | 20 | 19 | 19 | 18 | 18 | 18 | ||||||
| Retained Earnings Accumulated Deficit | -25 | -24 | -24 | -24 | -22 | -22 | -21 | -20 | -20 | -19 | -18 | -19 | ||||||
| Liabilities And Stockholders Equity | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 172 | 171 | 169 | 167 | 144 | 132 | 122 | 118 | 117 | 111 | 108 | 108 | ||||||
| Shares Outstanding | 172 | 171 | 169 | 167 | 144 | 132 | 122 | 118 | 117 | 111 | 108 | 108 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNascent Biotech Inc. (NBIO) — SEC Financial Statements & Analysis
Nascent Biotech Inc. (NBIO) is a pharmaceutical preparations company, incorporated in NV. Nascent Biotech Inc. trades on OTC as: NBIO. Nascent Biotech Inc. (NBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-14. Based on that filing, Nascent Biotech Inc. carries a market cap of $15.31M, a P/E ratio of -7.95x, a P/B ratio of -29.75x, a P/S ratio of 1498791.54x, an enterprise value of $15.32M, and an EV/EBITDA multiple of -7.32x. On profitability, it posts a gross margin of 594170.21%, an operating margin of -10618471.43%, a net margin of -9941342.86%, a Return on Equity (ROE) of 236.24%, and a Return on Assets (ROA) of -1256.79%. Per share, it reports EPS of $-0.01, diluted EPS of $-0.01, free cash flow per share of $-0.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -5.71% year-over-year, and EPS growth of -21.35% year-over-year. On the balance sheet, it maintains a current ratio of 0.31x, a quick ratio of 0.06x, working capital of $-514.54K, a debt-to-equity ratio of -1.44x, a debt ratio of 3.26, an interest coverage ratio of -14.01x, free cash flow of $-1.35M (TTM), and net debt of $11.61K. Figures sourced from SEC EDGAR.
- Market Cap
- $15.31M
- P/E TTM
- -7.95x
- EPS TTM
- $-0.01
- P/B TTM
- -29.75x
- ROE TTM
- 236.24%
- ROA TTM
- -1256.79%
- Debt To Equity
- -1.44x
- Free Cash Flow TTM
- $-1.35M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2024-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Nascent Biotech Inc. in?
Nascent Biotech Inc. (NBIO) operates in the Pharmaceutical Preparations industry.
What exchange does NBIO trade on?
Nascent Biotech Inc. (NBIO) trades on the OTC.
Where is Nascent Biotech Inc. incorporated?
Nascent Biotech Inc. is incorporated in NV.
When was Nascent Biotech Inc. (NBIO)'s most recent SEC filing?
Nascent Biotech Inc. (NBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-14.
What is NBIO's market cap?
Nascent Biotech Inc. (NBIO) has a market capitalization of $15.31M as of 2024-06-30.
What is NBIO's EPS (earnings per share)?
Nascent Biotech Inc. (NBIO)'s trailing twelve month EPS is $-0.01 as of 2024-06-30.
What is NBIO's ROE (return on equity)?
Nascent Biotech Inc. (NBIO)'s trailing twelve month Return on Equity (ROE) is 236.24% as of 2024-06-30.
What is NBIO's ROA (return on assets)?
Nascent Biotech Inc. (NBIO)'s trailing twelve month Return on Assets (ROA) is -1256.79% as of 2024-06-30.
What is NBIO's EV/EBITDA?
Nascent Biotech Inc. (NBIO)'s trailing twelve month EV/EBITDA is -7.32x as of 2024-06-30.